Company: GVH
Filing Date: 2025-10-01
Form Type: F-3
Source: 0001213900-25-094769
Chunk: 54

Company: Globavend Holdings Ltd
Filing Date: 2025-10-01
Form: F-3
Chunk 54
---
 other
jurisdictions, such as the United States. To the extent we choose to follow home country practices with respect to corporate governance
matters, our shareholders may be afforded less protection than they otherwise would under rules and regulations applicable to U.S. domestic
issuers.

As a result of all of the
above, our public shareholders may have more difficulty in protecting their interests in the face of actions taken by management, members
of the board of directors, or our Controlling Shareholder than they would as public shareholders of a company incorporated in the United States.
For a discussion of significant differences between the provisions of the Companies Act and the laws applicable to companies incorporated
in the United States and their shareholders, see “Risk Factors — Risks Related to Our Ordinary Shares — You may experience difficulties in effecting service of legal process, enforcing foreign judgments, or bringing original actions in the Cayman Islands or Hong Kong based on U.S. or other foreign laws, and the ability of U.S. authorities to bring actions in the Cayman Islands or Hong Kong may also be limited.”

<div align='center'>17</div>

Cayman Islands economic substance requirements may have an effect on our business and operations.

Pursuant to the International
Tax Cooperation (Economic Substance) Act, 2018 of the Cayman Islands (“ES Act”) that came into force on January 1, 2019,
a “relevant entity” is required to satisfy the economic substance test set out in the ES Act. A “relevant entity”
includes an exempted company incorporated in the Cayman Islands as is the Company; however, it does not include an entity that is tax
resident outside the Cayman Islands. Accordingly, currently, for so long as the Company is a tax resident outside the Cayman Islands (other
than excluded jurisdictions), it is not required to satisfy the economic substance test set out in the ES Act. The ES Act continues to
evolve and its application is subject to further clarification by regulatory authority. We may need to allocate additional resources to
keep updated with these developments, and we may have to make changes to our operations in order to comply with all requirements under
the ES Act.

We are a foreign private issuer within the meaning of the rules under the Exchange Act, and, as such, we are exempt from certain provisions applicable to U.S. domestic public companies.

Because we qualify as a foreign
private issuer under the Exchange Act, we are exempt from certain provisions of the securities rules and regulations in the